{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/melanoma-pigmented-lesions/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"2a182f91-5ece-564a-a4e3-83ea99005110","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field b1797417-1ed4-411c-b8d5-996675e2d8d0 --><h2>How should I assess a lesion?</h2><!-- end field b1797417-1ed4-411c-b8d5-996675e2d8d0 -->","summary":"","htmlStringContent":"<!-- begin item 24235488-7cbb-4d83-bb6d-7fd2feeceb24 --><!-- begin field 69bd84b6-f27f-4d7d-8342-25c7a25fec22 --><ul><li><strong>The key question to answer is whether the lesion could be a malignant melanoma.</strong></li><li><strong>Perform a history and examination </strong>to assess the possibility of melanoma. Examine the lesion in good light.<ul><li>Pigmented lesions which 'stand out from the crowd' because they are different (the 'Ugly Duckling sign') are a cause for concern, especially if they are changing.</li><li>A dermatoscope can be used to examine skin lesions and may more accurately distinguish between benign and malignant lesions, but this should only be done by a primary healthcare professional who has had adequate training in its use.</li></ul></li><li><strong>Use the Weighted 7-point checklist </strong>for assessment of pigmented skin lesions, and to determine referral.<ul><li>Major features of the lesion (2 points each):<ul><li>Change in size.</li><li>Irregular shape or border.</li><li>Irregular colour.</li></ul></li><li>Minor features of the lesion (1 point each):<ul><li>Largest diameter 7 mm or more.</li><li>Inflammation.</li><li>Oozing or crusting of the lesion.</li><li>Change in sensation (including itch).</li></ul></li><li>Suspicion is greater for lesions scoring 3 points or more. However, if there are strong concerns about cancer, any one feature is adequate to prompt urgent referral under the 2-week rule.</li><li>The following risk factors increase the risk of melanoma and should be factored at the time of assessment: family history of melanoma, personal history of melanoma, immunosuppression, excessive UV exposure including tanning beds. </li></ul></li><li><strong>Examine other areas.</strong><ul><li>Inspect the rest of the skin for suspicious pigmented lesions or dysplastic naevi.</li><li>Palpate major lymph nodes in the regional drainage area if the lesion is suspicious of melanoma. </li></ul></li></ul><!-- end field 69bd84b6-f27f-4d7d-8342-25c7a25fec22 --><!-- end item 24235488-7cbb-4d83-bb6d-7fd2feeceb24 -->","topic":{"id":"f5efb7d1-47fd-5e6a-a34d-95395f7523a0","topicId":"c296c560-d236-46ad-abcc-52c1fc0a1abf","topicName":"Melanoma and pigmented lesions","slug":"melanoma-pigmented-lesions","lastRevised":"Last revised in March 2017","chapters":[{"id":"6f710641-b9e2-5edc-aeed-890a7095cd96","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"88e3acd7-3799-5638-93fc-4739079b0f26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4cd2dca8-d311-5805-aea1-3870f6f4fccd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4b752af4-f177-5a66-a15f-20135ef4c005","slug":"changes","fullItemName":"Changes"},{"id":"a75a8fa4-d7d6-5932-b9a5-1d5af0bc564e","slug":"update","fullItemName":"Update"}]},{"id":"37450e93-1f0f-5e02-8d33-091798b27dd1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"37acfb65-9e83-5bb2-b261-3d35d43dc478","slug":"goals","fullItemName":"Goals"},{"id":"c2f69e41-ef64-5440-97db-a9d74ccdb90f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d7224a15-69f9-5519-a181-db44131ecc01","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5489c4c1-2dd5-5679-9dc8-3b4c8136dcb7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5779c9e-ebcd-5682-9817-797e8b88a2f6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0f3ef819-faeb-58c1-b3a8-029ddf2d2ec2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"97595147-c6d8-569e-8edd-b38e54974224","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b87206e4-fbe6-5ff3-b4db-757e2bdce473","slug":"definition","fullItemName":"Definition"},{"id":"7f5895c0-5070-5a7b-b402-836e18bde1fb","slug":"features","fullItemName":"Features"},{"id":"28380e7d-9dea-5a1f-9be7-1d7ac0e5a123","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7f9731f8-f8a0-5020-95ad-4220ee1b085a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fa22327f-becb-5e32-803b-7ff99e765cd1","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ed48057f-9e82-56c6-8846-040b30894b15","slug":"non-melanotic-lesions","fullItemName":"Non-melanotic lesions"},{"id":"aaaf9edb-2903-5b78-831c-b7839586fdfe","slug":"other-pigmented-lesions","fullItemName":"Other pigmented lesions"}]},{"id":"5b41a523-ea89-5f11-bbd5-21118fe0f7b2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2a182f91-5ece-564a-a4e3-83ea99005110","slug":"assessment","fullItemName":"Assessment"},{"id":"bb757fc9-32cf-5a88-b59d-3b676b8fe2f0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"260b59e0-5f81-5189-b2b1-781e2a96257a","slug":"biopsy-of-the-lesion","fullItemName":"Biopsy of the lesion"}]},{"id":"2a84a2c2-8b7a-582d-9ab2-4a4d23728f10","fullItemName":"Management","slug":"management","subChapters":[{"id":"01c409db-6041-5f5d-8faf-ad2b86d6a736","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b70563d4-10f0-517e-ab86-50e2e260e966","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"84e1f7c4-66db-59e5-b9a9-1fc097979aa4","slug":"evidence-on-the-abcd-7-point-checklists","fullItemName":"Evidence on the ABCD and 7-point checklists"},{"id":"68448720-3dbd-530e-bf51-0c8d618ee81e","slug":"evidence-on-self-examination-for-early-melanoma-detection","fullItemName":"Evidence on self-examination for early melanoma detection"}]},{"id":"560a3b23-0b91-5538-a7e7-2b8d61f1dfed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9e328671-9080-5494-aeca-8cca3a845389","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7968cb4d-c0a4-51ae-bc15-16ce3025ca18","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3daadc2-eacf-5bcf-8acb-473fa56481df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ede055-d8df-5c65-8d5e-4189da7ac034","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d2c30ae3-8839-58ef-8a53-f015bff32373","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"02f003b7-53e6-52fe-8c98-bc5580019357","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5b41a523-ea89-5f11-bbd5-21118fe0f7b2","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"60d2c0de-918a-51d0-a734-4a1cfe402f5b","slug":"basis-for-recommendation-5d0","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 5652efe8-4dd0-4e24-a813-c9d4391343a5 --><h3>Basis for recommendation</h3><!-- end field 5652efe8-4dd0-4e24-a813-c9d4391343a5 -->","summary":null,"htmlStringContent":"<!-- begin item 5d0d5941-b23d-4914-b14a-b41b11db2c85 --><!-- begin field f85d3f81-8e14-401c-9658-087f44c527b5 --><p>There is evidence from several studies comparing the sensitivity and specificity of the ABCD(E) rule and 7-point checklist (see evidence section). </p><p>However, [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2015a</a>] recommends using the weighted 7 point checklist for the identification of lesions which should be referred urgently using the <a href=\"https://www.nice.org.uk/guidance/ng12/chapter/terms-used-in-this-guideline#terms-used-in-this-guideline\" data-hyperlink-id=\"8013d08c-ef54-4098-af56-a98c00e36dba\">suspected cancer pathway referral</a>. The person should receive an appointment within 2 weeks and assessed by a competent professional. NICE also suggests the referral of people if dermoscopy suggests melanoma or if there is a pigmented or non-pigmented lesion suspicious of nodular melanoma. </p><h4>Dermoscopy</h4><ul><li>A dermatoscope is a hand-held light magnifier which can be used to visualize subsurface structures of a lesion, such as dots, streaks, veils, and networks, which can help to diagnose pigmented (or suspected pigmented) lesions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Rigel et al, 2010</a>].</li><li>Guidelines on <em>Improving outcomes for people with skin tumours including melanoma </em>from the National Institute for Health and Clinical Excellence acknowledge that the dermatoscope is an important diagnostic aid that can be used to examine skin lesions and help to distinguish benign from malignant pigmented lesions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2016b</a>]. </li></ul><!-- end field f85d3f81-8e14-401c-9658-087f44c527b5 --><!-- end item 5d0d5941-b23d-4914-b14a-b41b11db2c85 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}